Colin Kerr
Published: Monday, November 23, 2020

AstraZeneca and the University of Oxford have announced that positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19.
https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%.
Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial at Oxford, said: “These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.”
Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said:
‘The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by SARS-CoV-2. We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multi-national effort which will reap benefits for the whole world.’
Tags: oxford vaccine trial astazeneca
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
Read more...
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Read more...
ESCRS Today 2025: All Eyes on Innovation
Watching out for obstacles and opportunities
Read more...
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Read more...
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Read more...
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Read more...
Supplement: ESCRS Clinical Trends Series: Presbyopia
Read more...
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Read more...
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Read more...
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.
Read more...